Roche wins FDA nod for hep C diagnostic

By Damian Garde Roche ($RHHBY) has secured the FDA’s blessing for a new viral load hepatitis C test, designed to gauge a patient’s response to treatment by identifying ...

Saladax secures $22.4M from Chinese pharma giant

The cash will help Saladax expand access to its cancer treatment dose Dx tests By Mark Hollmer Saladax Biomedical drew a $22.4 million cash infusion from a major Chinese pharmaceutical ...

Report: Life Tech may have found a buyer after all

By Damian Garde The hot and cold rumors over a potential Life Technologies ($LIFE) sale have swung back toward the former, as Bloomberg‘s sources say a team of private equity ...

Analysts startled as Boston Scientific holds back Watchman data

By Damian Garde Boston Scientific ($BSX) is slated to present late-breaking study data on its much-anticipated Watchman device, but now the company says it will only unveil some ...

Edwards’ last laugh: Medtronic pays $83.6M in heart valve patent suit

By Mark Hollmer Medtronic ($MDT) will fork over $83.6 million to Edwards Lifesciences ($EW) to settle a 2010 jury verdict it lost in a battle over heart valve patents. Edwards disclosed ...

Royalty Pharma Meeting With Elan Investors on Bid

By Makiko Kitamura & Allison Connolly Royalty Pharma said it’s meeting with as many as 15 Elan Corp. (ELN) shareholders from today to persuade them to accept its offer to ...

Pfizer painkiller gets longer patent protection

Pfizer gets 18 months more patent protection for blockbuster painkiller, sues generic makers By Linda a. Johnson Drugmaker Pfizer Inc. said Tuesday that a new patent on one of its ...

Takeda Put Actos Sales Ahead of User Safety, Witness Says

By Jef Feeley Takeda Pharmaceutical Co. (4502), Asia’s biggest drugmaker, put sales of its Actos diabetes drug ahead of concerns about consumer safety, a witness testified in ...

3 Biotechs Still Burning Through Cash: Ariad Pharmaceuticals, Inc. (ARIA), Dynavax Technologies Corporation (DVAX), MannKind Corporation (MNKD)

By THE MOTLEY FOOL Young, upstart pharmaceutical and biotech companies do one thing that almost no other industry does. They go years without generating any revenue. Thanks to investors, ...

Biotech Tetraphase Pharmaceutical sets terms for $75 million IPO

By Renaissance Capital Tetraphase Pharmaceuticals, a biotech creating antibiotics to treat life-threatening multi-drug resistant infections, announced terms for its IPO on Tuesday. ...

Bergen firm Par to pay $45M fine for illegal marketing

BY  HUGH R. MORLEY It was the kind of high-intensity sales push designed to guarantee results. The marketing department drew up a list of customers who had used a similar product, ...

AstraZeneca Pharma hits 52-week low on promoter stake sale plan

AstraZeneca Pharmaceuticals AB Sweden has decided to reduce its shareholding in the company to meet minimum public shareholding norm. AstraZeneca Pharma India has dipped almost 10% ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS